Table. 1 Baseline characteristics
Characteristics | Training cohort (n = 218) | Validation cohort (n = 93) | Test cohort 1 (n = 96) | Test cohort 2 (n = 26,256) | Prognosis cohort (n = 390,574) |
|---|---|---|---|---|---|
Male | 68 (31%) | 45 (48%) | 68 (71%) | 12,605 (48%) | 180,501 (46%) |
Age | 30.79 (11.35) | 31.65 (9.87) | 41.14 (11.79) | 54.91 (7.51) | 56.56 (8.09) |
BMI | 39.05 (7.42) | 39.54 (6.43) | 26.85 (3.65) | 26.48 (4.13) | 27.42 (4.77) |
ALT | 48.96 (39.82) | 53.11 (34.16) | 73.99 (60.18) | 22.93 (13.77) | 23.50 (13.98) |
AST | 35.86 (22.68) | 38.97 (24.62) | 48.45 (33.75) | 25.69 (9.91) | 26.14 (9.96) |
GGT | 46.65 (32.30) | 57.50 (45.22) | 75.04 (82.75) | 33.39 (32.51) | 37.21 (40.87) |
Albumin | 44.03 (3.34) | 44.24 (3.10) | 46.46 (3.57) | 45.43 (2.52) | 45.22 (2.61) |
Total bilirubin | 10.63 (4.42) | 10.62 (3.61) | 14.56 (6.95) | 9.39 (4.56) | 9.11 (4.36) |
Uric acid | 425.09 (118.70) | 442.64 (127.14) | 412.03 (116.85) | 5.30 (1.22) | 5.41 (1.38) |
HbA1c | 6.05 (1.15) | 6.21 (1.17) | 6.41 (1.65) | 5.36 (0.47) | 5.45 (0.61) |
Triglycerides | 2.10 (1.12) | 2.20 (1.04) | 2.60 (1.62) | 1.64 (0.94) | 1.75 (1.02) |
Total cholesterol | 5.10 (0.92) | 5.14 (1.05) | 5.09 (1.17) | 5.73 (1.08) | 5.70 (1.14) |
HDL-C | 1.16 (0.22) | 1.17 (0.21) | 1.00 (0.22) | 1.48 (0.38) | 1.45 (0.38) |
LDL-C | 3.24 (0.63) | 3.23 (0.74) | 3.06 (0.89) | 3.58 (0.83) | 3.56 (0.87) |
MASH | 96 (44%) | 45 (48%) | 43 (45%) | 1168 (4.4%) | - |
